DB107 (Toca 511 & Toca FC)

About Denovo Biopharma

Denovo Biopharma is a San Diego and Beijing-based biotech with a disruptive 'asset regeneration' strategy. It in-licenses failed or shelved late-stage drug candidates and applies its proprietary genomics platform to discover novel predictive biomarkers from residual clinical trial samples. By using these biomarkers as companion diagnostics to select responsive patients in new, smaller trials, Denovo aims to de-risk and accelerate the development of personalized medicines in oncology and neuroscience at a fraction of the traditional cost and time. The company is privately held and has advanced several programs into late-stage global trials.

Therapeutic Areas

Other Recurrent High-Grade Glioma Drugs